This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].
Data di pubblicazione: | 2019 | |
Titolo: | AISF position paper on HCV in immunocompromised patients | |
Autori: | ||
Citazione: | Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022]. | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.dld.2018.09.022 | |
Abstract: | This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era. | |
URL: | http://www.elsevier.com/wps/find/journalbibliographicinfo.cws_home/623449/description#bibliographicinfo | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
PETTA DLD 2019.pdf | Versione Editoriale | Administrator Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.